212 related articles for article (PubMed ID: 36031498)
1. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
2. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
3. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
4. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
5. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Cornes P; Simera I; Collingwood M; Williams C; Kitchener H
Cochrane Database Syst Rev; 2007 Apr; (2):CD003916. PubMed ID: 17443533
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis.
Narasimhulu DM; Cope A; Riaz IB; Petersen I; Cilby W; Langstraat C; Glaser G; Kumar A; Cappuccio S; Murad MH; West C; Mariani A
Int J Gynecol Cancer; 2020 Jun; 30(6):797-805. PubMed ID: 32221021
[TBL] [Abstract][Full Text] [Related]
9. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
van den Heerik ASVM; Horeweg N; de Boer SM; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2021 Apr; 31(4):594-604. PubMed ID: 33082238
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
12. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium
Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.
; Blake P; Swart AM; Orton J; Kitchener H; Whelan T; Lukka H; Eisenhauer E; Bacon M; Tu D; Parmar MK; Amos C; Murray C; Qian W
Lancet; 2009 Jan; 373(9658):137-46. PubMed ID: 19070891
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Mar; (3):CD003916. PubMed ID: 22419290
[TBL] [Abstract][Full Text] [Related]
15. Vaginal brachytherapy management of stage I and II endometrial cancer.
van den Heerik ASVM; Horeweg N; Creutzberg CL; Nout RA
Int J Gynecol Cancer; 2022 Mar; 32(3):304-310. PubMed ID: 35256416
[TBL] [Abstract][Full Text] [Related]
16. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
Wortman BG; Bosse T; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld H; van den Berg H; Slot A; De Winter KAJ; Verhoeven-Adema KW; Smit VTHBM; Creutzberg CL;
Gynecol Oncol; 2018 Oct; 151(1):69-75. PubMed ID: 30078506
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
[TBL] [Abstract][Full Text] [Related]
18. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
19. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
Creutzberg CL; van Putten WL; Koper PC; Lybeert ML; Jobsen JJ; Wárlám-Rodenhuis CC; De Winter KA; Lutgens LC; van den Bergh AC; van de Steen-Banasik E; Beerman H; van Lent M
Lancet; 2000 Apr; 355(9213):1404-11. PubMed ID: 10791524
[TBL] [Abstract][Full Text] [Related]
20. The role of adjuvant radiation in endometrial cancer.
Diavolitsis V; Boyle J; Singh DK; Small W
Oncology (Williston Park); 2009 Apr; 23(4):342-9. PubMed ID: 19476264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]